Split History
MDGL split history picture
Madrigal Pharmaceuticals (MDGL) has 1 split in our MDGL split history database. The split for MDGL took place on July 25, 2016. This was a 1 for 35 reverse split, meaning for each 35 shares of MDGL owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 28.5714285714286 share position following the split.

When a company such as Madrigal Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the MDGL split history from start to finish, an original position size of 1000 shares would have turned into 28.5714285714286 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Madrigal Pharmaceuticals shares, starting with a $10,000 purchase of MDGL, presented on a split-history-adjusted basis factoring in the complete MDGL split history. MDGL split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 04/24/2014
End date: 04/22/2024
Start price/share: $145.25
End price/share: $213.49
Dividends collected/share: $0.00
Total return: 46.98%
Average Annual Total Return: 3.93%
Starting investment: $10,000.00
Ending investment: $14,704.67
Years: 10.00
Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Co.'s primary product candidate, resmetirom, is being developed as a once-daily oral pill to treat several disease states, including non-alcoholic steatohepatitis, or NASH. Co. has initiated MAESTRO-NASH, a Phase 3 trial in NASH with its once daily, oral thyroid hormone receptor beta selective agonist, resmetirom. Co. has opened for enrollment MAESTRO-NAFLD-1, a Phase 3 clinical study of patients with biopsy-confirmed or presumed NASH recruited from sites in the U.S. According to our MDGL split history records, Madrigal Pharmaceuticals has had 1 split.
Date Ratio
07/25/20161 for 35
MDGL is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

MDGN Split History
MDT Split History
MDVN Split History
MDXG Split History
MEIP Split History
MELA Split History
MGEN Split History
MLNT Split History
MMM Split History
MMSI Split History

Also explore: MDGL shares outstanding history

Email EnvelopeFree MDGL Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Applied DNA Sciences, Inc. (APDN)
Cidara Therapeutics, Inc. (CDTX)
Smart for Life, Inc. (SMFL)
Windtree Therapeutics, Inc. (WINT)
Golden Sun Health Technology Group Limited (GSUN)
Zapp Electric Vehicles Group Limited (ZAPP)
Beneficient (BENF)
MySize, Inc. (MYSZ)
Gorilla Technology Group Inc. (GRRR)
Sunshine Biopharma, Inc. (SBFM)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

MDGL Insider Buying

MDGL Split History | www.SplitHistory.com | Copyright © 2013 - 2024, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.